In May 2024, Knight entered into an agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (now part of Collegium Pharmaceutical, Inc.; ...
While current guidelines from the American Academy ... or cannot tolerate one or more stimulants an alternative treatment option. ADHD is caused by a deficit in response inhibition, an executive ...
Neurodiversity is a concept that embraces the different ways that the human brain processes information, functions, and presents behaviourally.1 Instead of thinking in terms of a medical disability ...
Knight Therapeutics Inc. ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PMtm, an extended-release formulation of ...
Intrinsic motivation (DMQ total score). ADHD medication status (medicated vs unmedicated). Adherence to assigned programme (number of sessions completed). Family functioning (PSI total score).
The Canadian Medical Association Journal has published the updated guidelines for treatment of opioid use disorder that "strongly recommends" evidence-based treatments and harm reduction strategies.
On November 18, 2024, Elite Pharmaceuticals, Inc. (Elite) announced in a press release that it had secured approval from the US Food and Drug Administration (FDA) for a generic version of Vyvanse® ...